Novo Nordisk has done something pharmaceutical companies almost never do: they are running a direct head-to-head trial comparing their amylin/GLP-1 combination CagriSema against Eli Lilly’s GIP/GLP-1 dual agonist tirzepatide (Zepbound). This is not a comparison pieced together from separate trials with different populations and endpoints. It is the same patients, same timeframe, same primary outcome. When this data reports, it will be the most important trial readout for the body-composition community since retatrutide’s TRIUMPH program.
⚡ Key Takeaway
CagriSema (amylin + GLP-1) vs tirzepatide (GIP + GLP-1) is the head-to-head trial that will determine which dual-mechanism approach produces better body composition outcomes. CagriSema's amylin component may preserve more muscle. Tirzepatide has a proven efficacy record. The REDEFINE program will provide the definitive answer.
The Two Mechanisms Compared
CagriSema = Amylin + GLP-1. Combines cagrilintide (long-acting amylin analog) with semaglutide (GLP-1 agonist). The amylin component adds satiety through a separate brain pathway, modulates energy expenditure, and may favorably influence metabolic partitioning — how the body decides what to burn during caloric deficit. Phase 2 showed 22.7% weight loss at 68 weeks.
Tirzepatide = GIP + GLP-1. Simultaneously activates GLP-1 and GIP receptors. The GIP component enhances insulin secretion and works synergistically with GLP-1 on appetite. Phase 3 (SURMOUNT) showed approximately 22% weight loss at 72 weeks with the highest dose. Already FDA-approved as Zepbound.
Both approaches layer a second mechanism on top of GLP-1. The question is which second mechanism produces better outcomes, particularly for body composition rather than just scale weight.
Why the Muscle Question Dominates
Both drugs will produce significant fat loss. The differentiator for the physique community is not total weight lost but the composition of that weight loss. If CagriSema’s amylin component produces meaningfully better lean-mass preservation than tirzepatide’s GIP component, it becomes the preferred drug for men who train — even if total weight loss is similar.
The amylin-pathway hypothesis suggests that amylin receptor activation influences substrate selection during energy deficit, favoring fat oxidation over muscle protein catabolism. The GIP-pathway hypothesis is less directly tied to muscle preservation — GIP primarily enhances the metabolic effects of GLP-1 rather than independently modulating body composition partitioning.
Both hypotheses need the head-to-head data to confirm. Until then, the muscle-preservation advantage is theoretical for CagriSema and undemonstrated for tirzepatide relative to CagriSema specifically.
What to Watch For
The REDEFINE program is Novo Nordisk’s Phase 3 trial series for CagriSema. The head-to-head comparison with tirzepatide is the most anticipated component. Key variables to watch when data reports: total weight loss (the headline number), lean-mass change as a percentage of total weight lost (the physique-relevant number), gastrointestinal tolerability (the compliance-relevant number), and achievement of clinically meaningful thresholds (percentage reaching 10%, 15%, 20% weight loss).
If CagriSema demonstrates both comparable total weight loss and superior lean-mass preservation, it becomes the de facto choice for physique-focused users. If the total weight loss is comparable but the composition is similar, the market will differentiate on side effects, dosing convenience, and price. If tirzepatide wins on total weight loss, the extra pounds of fat lost may outweigh the composition advantage for many users.